Your browser doesn't support javascript.
loading
How to design a study to evaluate therapeutic drug monitoring in infectious diseases?
Märtson, A-G; Sturkenboom, M G G; Stojanova, J; Cattaneo, D; Hope, W; Marriott, D; Patanwala, A E; Peloquin, C A; Wicha, S G; van der Werf, T S; Tängdén, T; Roberts, J A; Neely, M N; Alffenaar, J-W C.
Affiliation
  • Märtson AG; University of Groningen, University Medical Centre Groningen, Department of Clinical Pharmacy and Pharmacology, Groningen, the Netherlands.
  • Sturkenboom MGG; University of Groningen, University Medical Centre Groningen, Department of Clinical Pharmacy and Pharmacology, Groningen, the Netherlands.
  • Stojanova J; Interdisciplinary Centre for Health Studies (CIESAL), Universidad de Valparaíso, Valparaíso, Chile.
  • Cattaneo D; ASST Fatebenefratelli Sacco University Hospital, Unit of Clinical Pharmacology, Department of Laboratory Medicine, Milan, Italy.
  • Hope W; University of Liverpool, Antimicrobial Pharmacodynamics and Therapeutics, Liverpool, UK; Royal Liverpool Broadgreen University Hospital Trust, Liverpool, United Kingdom.
  • Marriott D; St Vincent's Hospital, Sydney, Australia.
  • Patanwala AE; The University of Sydney, Sydney Pharmacy School, Sydney, New South Wales, Australia; Royal Prince Alfred Hospital, Sydney, Australia.
  • Peloquin CA; Infectious Disease Pharmacokinetics Laboratory, College of Pharmacy, Emerging Pathogens Institute, University of Florida, Gainesville, FL, USA.
  • Wicha SG; University of Hamburg, Department of Clinical Pharmacy, Institute of Pharmacy, Hamburg, Germany.
  • van der Werf TS; University of Groningen, University Medical Centre Groningen, Department of Pulmonary Diseases and Tuberculosis, Groningen, the Netherlands; University of Groningen, University Medical Centre Groningen, Department of Internal Medicine, Groningen, the Netherlands.
  • Tängdén T; Uppsala University, Department of Medical Sciences, Uppsala, Sweden.
  • Roberts JA; University of Queensland Centre for Clinical Research, Faculty of Medicine & Centre for Translational Anti-infective Pharmacodynamics, School of Pharmacy, The University of Queensland, Brisbane, Australia; Departments of Pharmacy and Intensive Care Medicine, Royal Brisbane and Women's Hospital,
  • Neely MN; Children's Hospital of Los Angeles, Laboratory of Applied Pharmacokinetics and Bioinformatics, Los Angeles, CA, USA.
  • Alffenaar JC; University of Groningen, University Medical Centre Groningen, Department of Clinical Pharmacy and Pharmacology, Groningen, the Netherlands; The University of Sydney, Sydney Pharmacy School, Sydney, New South Wales, Australia; Westmead Hospital, Sydney, Australia; Marie Bashir Institute of Infectious
Clin Microbiol Infect ; 26(8): 1008-1016, 2020 Aug.
Article in En | MEDLINE | ID: mdl-32205294
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Communicable Diseases / Drug Monitoring / Anti-Bacterial Agents Type of study: Guideline Limits: Humans Language: En Journal: Clin Microbiol Infect Journal subject: DOENCAS TRANSMISSIVEIS / MICROBIOLOGIA Year: 2020 Document type: Article Affiliation country: Países Bajos
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Communicable Diseases / Drug Monitoring / Anti-Bacterial Agents Type of study: Guideline Limits: Humans Language: En Journal: Clin Microbiol Infect Journal subject: DOENCAS TRANSMISSIVEIS / MICROBIOLOGIA Year: 2020 Document type: Article Affiliation country: Países Bajos